[go: up one dir, main page]

WO2024086246A3 - 2-substituted 3,4 a, 5, 7, 8, 8 a-hexahydro-4h-thiop yrano [4,3- djpyrimidin-4-ones for wound treatment - Google Patents

2-substituted 3,4 a, 5, 7, 8, 8 a-hexahydro-4h-thiop yrano [4,3- djpyrimidin-4-ones for wound treatment Download PDF

Info

Publication number
WO2024086246A3
WO2024086246A3 PCT/US2023/035442 US2023035442W WO2024086246A3 WO 2024086246 A3 WO2024086246 A3 WO 2024086246A3 US 2023035442 W US2023035442 W US 2023035442W WO 2024086246 A3 WO2024086246 A3 WO 2024086246A3
Authority
WO
WIPO (PCT)
Prior art keywords
yrano
thiop
djpyrimidin
hexahydro
ones
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2023/035442
Other languages
French (fr)
Other versions
WO2024086246A8 (en
WO2024086246A2 (en
Inventor
John Joseph Palsted DELGADO
Daniel D. Holsworth
Sarika SARASWATI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eluciderm Inc
Original Assignee
Eluciderm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU2023365200A priority Critical patent/AU2023365200A1/en
Priority to JP2025522125A priority patent/JP2025535316A/en
Priority to CN202380085227.8A priority patent/CN120500488A/en
Priority to KR1020257016221A priority patent/KR20250093525A/en
Priority to EP23805742.6A priority patent/EP4605084A2/en
Priority to IL320183A priority patent/IL320183A/en
Application filed by Eluciderm Inc filed Critical Eluciderm Inc
Publication of WO2024086246A2 publication Critical patent/WO2024086246A2/en
Publication of WO2024086246A3 publication Critical patent/WO2024086246A3/en
Priority to MX2025004545A priority patent/MX2025004545A/en
Anticipated expiration legal-status Critical
Publication of WO2024086246A8 publication Critical patent/WO2024086246A8/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions.
PCT/US2023/035442 2022-10-18 2023-10-18 2-substituted 3,4 a, 5, 7, 8, 8 a-hexahydro-4h-thiop yrano [4,3- djpyrimidin-4-ones for wound treatment Ceased WO2024086246A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
JP2025522125A JP2025535316A (en) 2022-10-18 2023-10-18 2-Substituted 3,4a,5,7,8,8a-hexahydro-4H-thiopyrano[4,3-d]pyrimidin-4-ones for wound treatment
CN202380085227.8A CN120500488A (en) 2022-10-18 2023-10-18 2-Substituted 3,4a,5,7,8 a-hexahydro-4H-thiopyrano [4,3-d ] pyrimidin-4-ones for wound treatment
KR1020257016221A KR20250093525A (en) 2022-10-18 2023-10-18 2-Substituted 3,4A,5,7,8,8A-Hexahydro-4H-thiopyrano[4,3-D]pyrimidin-4-ones for wound healing
EP23805742.6A EP4605084A2 (en) 2022-10-18 2023-10-18 2-substituted 3,4 a, 5, 7, 8, 8 a-hexahydro-4h-thiop yrano [4,3- d]pyrimidin-4-ones for wound treatment
IL320183A IL320183A (en) 2022-10-18 2023-10-18 2-substituted 3,4 a, 5, 7, 8, 8 a-hexahydro-4h-thiop yrano [4,3- djpyrimidin-4-ones for wound treatment
AU2023365200A AU2023365200A1 (en) 2022-10-18 2023-10-18 2-substituted 3,4 a, 5, 7, 8, 8 a-hexahydro-4h-thiop yrano [4,3- d]pyrimidin-4-ones for wound treatment
MX2025004545A MX2025004545A (en) 2022-10-18 2025-04-16 2-substituted 3,4 a, 5, 7, 8, 8 a-hexahydro-4h-thiop yrano [4,3- djpyrimidin-4-ones for wound treatment

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202263417257P 2022-10-18 2022-10-18
US63/417,257 2022-10-18
US202263418956P 2022-10-24 2022-10-24
US202263418947P 2022-10-24 2022-10-24
US63/418,947 2022-10-24
US63/418,956 2022-10-24

Publications (3)

Publication Number Publication Date
WO2024086246A2 WO2024086246A2 (en) 2024-04-25
WO2024086246A3 true WO2024086246A3 (en) 2024-05-30
WO2024086246A8 WO2024086246A8 (en) 2025-05-22

Family

ID=88793232

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/035442 Ceased WO2024086246A2 (en) 2022-10-18 2023-10-18 2-substituted 3,4 a, 5, 7, 8, 8 a-hexahydro-4h-thiop yrano [4,3- djpyrimidin-4-ones for wound treatment

Country Status (8)

Country Link
EP (1) EP4605084A2 (en)
JP (1) JP2025535316A (en)
KR (1) KR20250093525A (en)
CN (1) CN120500488A (en)
AU (1) AU2023365200A1 (en)
IL (1) IL320183A (en)
MX (1) MX2025004545A (en)
WO (1) WO2024086246A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025194162A1 (en) * 2024-03-15 2025-09-18 Eluciderm Inc. Pharmaceutical compositions of wnt pathway inhibitors for wound treatment

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1142881A1 (en) * 1999-01-14 2001-10-10 Meiji Seika Kaisha Ltd. Poly(adp-ribose) polymerase inhibitors consisting of pyrimidine derivatives

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
ES8702440A1 (en) 1984-10-04 1986-12-16 Monsanto Co Prolonged release of biologically active somatotropins.
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (en) 1989-03-22 1991-07-25 Bioresearch Spa USE OF 5 METHYLTHETRAHYDROPHOLIC ACID, 5 FORMYLTHETRAHYDROPHOLIC ACID AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS IN THE FORM OF CONTROLLED RELEASE ACTIVE IN THE THERAPY OF MENTAL AND ORGANIC DISORDERS.
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
IT1270594B (en) 1994-07-07 1997-05-07 Recordati Chem Pharm CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION OF LIQUID SUSPENSION MOGUISTEIN
ATE268591T1 (en) 1995-06-27 2004-06-15 Takeda Chemical Industries Ltd METHOD FOR PRODUCING DELAYED RELEASE PREPARATIONS
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
JP2909418B2 (en) 1995-09-18 1999-06-23 株式会社資生堂 Delayed release microsphere of drug
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6419961B1 (en) 1996-08-29 2002-07-16 Takeda Chemical Industries, Ltd. Sustained release microcapsules of a bioactive substance and a biodegradable polymer
CA2217134A1 (en) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
PT839525E (en) 1996-10-31 2004-10-29 Takeda Chemical Industries Ltd PROLONGED LIBERATION PREPARATION
AU7871298A (en) 1996-12-20 1998-07-17 Takeda Chemical Industries Ltd. Method of producing a sustained-release preparation
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
KR19990085365A (en) 1998-05-16 1999-12-06 허영섭 Biodegradable polymer microspheres capable of continuously controlled controlled release and preparation method thereof
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
WO2019071242A1 (en) 2017-10-06 2019-04-11 Eluciderm Inc. Compositions and methods for wound treatment
AU2022342141A1 (en) 2021-09-13 2024-04-04 Eluciderm Inc. Composition for use in a method for cartilage regeneration and regrowth following injury

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1142881A1 (en) * 1999-01-14 2001-10-10 Meiji Seika Kaisha Ltd. Poly(adp-ribose) polymerase inhibitors consisting of pyrimidine derivatives

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BASTAKOTY, D. ET AL., FASEB J, vol. 29, no. 12, 2015, pages 4881 - 4892, XP055806117 *
CHEMICAL LIBRARY: "thiopyrane derivatives", 30 January 2017 (2017-01-30), pages 1 - 1, XP093121570, Retrieved from the Internet <URL:www.stn.org> [retrieved on 20240119] *
CHEMICAL LIBRARY: "thiopyrano derivatives", STN, 17 June 2015 (2015-06-17), pages 1 - 1, XP093121589, Retrieved from the Internet <URL:www.stn.org> [retrieved on 20240119] *
FUMIYUKI SHIRAI ET AL: "Discovery of Novel Spiroindoline Derivatives as Selective Tankyrase Inhibitors", JOURNAL OF MEDICINAL CHEMISTRY, vol. 62, no. 7, 18 March 2019 (2019-03-18), US, pages 3407 - 3427, XP055650171, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.8b01888 *
MOSER U ET AL: "STRUKTUR- UND KONFORMATIONS-WIRKUNGS-BEZIEHUNGEN HETEROCYCLISCHER ACETYLCHOLINANALOGA, 18. MITT SYNTHESE UND MUSKARINARTIGE WIRKUNG VON ESTERN DES SULFOARECAIDINS UND SULFOISOARECAIDINS STRUCTURE- AND CONFORMATION-ACTIVITY RELATIONSHIPS OF HETEROCYCLIC ACETYLCHOLINE ANALOGUES, XVIII: SYNTHESIS AND M", ARCHIV DER PHARMAZIE, WILEY VERLAG, WEINHEIM, vol. 316, no. 8, 1 January 1983 (1983-01-01), pages 670 - 677, XP001014590, ISSN: 0365-6233, DOI: 10.1002/ARDP.19833160805 *

Also Published As

Publication number Publication date
MX2025004545A (en) 2025-06-02
WO2024086246A8 (en) 2025-05-22
EP4605084A2 (en) 2025-08-27
CN120500488A (en) 2025-08-15
KR20250093525A (en) 2025-06-24
AU2023365200A1 (en) 2025-05-15
IL320183A (en) 2025-06-01
WO2024086246A2 (en) 2024-04-25
JP2025535316A (en) 2025-10-24

Similar Documents

Publication Publication Date Title
WO2018218070A3 (en) Covalent inhibitors of kras
EP4023659A4 (en) Compound and drug conjugate, and preparation method and use thereof
MX2024003738A (en) Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds.
WO2019178191A8 (en) O-glycoprotein-2-acetamido-2-deoxy-3-d-glycopyranosidase inhibitors
WO2023078333A8 (en) Substituted phenylpropionic acid derivative and use thereof
PH12021552513A1 (en) Pyrrole compounds
WO2020126968A3 (en) Urea derivatives for use against proliferative diseases
MX2021007247A (en) Rapamycin derivatives.
MY200061A (en) Irak inhibitor and preparation method therefor and use thereof
CR20210181A (en) O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors
WO2022106902A8 (en) Benzenesulfonamide derivatives and uses thereof
WO2023122260A3 (en) Inhibitors of sars-cov-2
PH12021552953A1 (en) Tricyclic compounds
WO2024086246A3 (en) 2-substituted 3,4 a, 5, 7, 8, 8 a-hexahydro-4h-thiop yrano [4,3- djpyrimidin-4-ones for wound treatment
EP4361135A4 (en) Small-molecule compound, and use thereof and preparation method therefor
CA3155875A1 (en) Sulfo-substituted biaryl compounds or salts thereof and preparation method and use thereof
PH12022550254A1 (en) MICROMOLECULE PI4KIIIa INHIBITOR COMPOSITION, PREPARATION METHOD THEREFOR AND USE THEREOF
EP3964520A4 (en) Novel oligopeptide, and pharmaceutical composition for preventing or treating cancer, comprising same as active ingredient
WO2022234337A3 (en) Crystalline carbazole derivative
WO2020139971A3 (en) Methods for making dimeric naphthalimides and solid state forms of the same
EP3964218A4 (en) Pharmaceutical composition for preventing or treating myositis, comprising isolated mitochondria as active ingredient
ZA202400679B (en) Dimethyl-substituted thiazololactam compound and use thereof
WO2024054661A3 (en) Dynamin activators
WO2023141522A3 (en) Multicyclic compounds
HK40112968A (en) Processes for the preparation of 1,2,3,5,6,7-hexahydro-s-indacene derivatives

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23805742

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 320183

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: MX/A/2025/004545

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2025522125

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2025522125

Country of ref document: JP

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112025007630

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 821099

Country of ref document: NZ

Ref document number: AU2023365200

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 821099

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2023365200

Country of ref document: AU

Date of ref document: 20231018

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20257016221

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 202517047378

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2025112994

Country of ref document: RU

Ref document number: 2023805742

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2023805742

Country of ref document: EP

Effective date: 20250519

WWE Wipo information: entry into national phase

Ref document number: 11202502627W

Country of ref document: SG

WWP Wipo information: published in national office

Ref document number: 11202502627W

Country of ref document: SG

WWP Wipo information: published in national office

Ref document number: MX/A/2025/004545

Country of ref document: MX

WWP Wipo information: published in national office

Ref document number: 202517047378

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 202380085227.8

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 1020257016221

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 202380085227.8

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2023805742

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2025112994

Country of ref document: RU